JP2008520548A - 薬剤耐性癌、薬剤耐性ウイルス感染症および薬剤耐性微生物感染症におけるノルジヒドログアヤレト酸誘導体の使用 - Google Patents

薬剤耐性癌、薬剤耐性ウイルス感染症および薬剤耐性微生物感染症におけるノルジヒドログアヤレト酸誘導体の使用 Download PDF

Info

Publication number
JP2008520548A
JP2008520548A JP2007535772A JP2007535772A JP2008520548A JP 2008520548 A JP2008520548 A JP 2008520548A JP 2007535772 A JP2007535772 A JP 2007535772A JP 2007535772 A JP2007535772 A JP 2007535772A JP 2008520548 A JP2008520548 A JP 2008520548A
Authority
JP
Japan
Prior art keywords
amino acid
acid residue
group
residue
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007535772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520548A5 (enExample
Inventor
デイビッド イー． モールド，
ユアン シー． リー，
チー−チュアン チャン，
ル チー シー． ファン，
チー−ル フー，
ミン−ホア スウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2008520548A publication Critical patent/JP2008520548A/ja
Publication of JP2008520548A5 publication Critical patent/JP2008520548A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007535772A 2004-10-06 2005-10-06 薬剤耐性癌、薬剤耐性ウイルス感染症および薬剤耐性微生物感染症におけるノルジヒドログアヤレト酸誘導体の使用 Withdrawn JP2008520548A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61611404P 2004-10-06 2004-10-06
PCT/US2005/035795 WO2006041902A2 (en) 2004-10-06 2005-10-06 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection

Publications (2)

Publication Number Publication Date
JP2008520548A true JP2008520548A (ja) 2008-06-19
JP2008520548A5 JP2008520548A5 (enExample) 2008-11-20

Family

ID=36148866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007535772A Withdrawn JP2008520548A (ja) 2004-10-06 2005-10-06 薬剤耐性癌、薬剤耐性ウイルス感染症および薬剤耐性微生物感染症におけるノルジヒドログアヤレト酸誘導体の使用

Country Status (8)

Country Link
US (1) US20080207532A1 (enExample)
EP (1) EP1848418A4 (enExample)
JP (1) JP2008520548A (enExample)
CN (1) CN101437505A (enExample)
AU (1) AU2005294432A1 (enExample)
CA (1) CA2583336A1 (enExample)
MX (1) MX2007004025A (enExample)
WO (1) WO2006041902A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505567A (ja) * 2012-02-03 2015-02-23 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｎｄｇａ誘導体およびソラフェニブを含む組成物、ならびにがんの処置におけるこれらの使用
JP2016516007A (ja) * 2013-02-26 2016-06-02 トリアクト セラピューティクス，インク． 癌治療
JP2016521278A (ja) * 2013-05-02 2016-07-21 ヘルパービー セラピューティクス リミテッドＨｅｌｐｅｒｂｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ノルジヒドログアヤレト酸およびアミノグリコシドの組み合わせ

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027337A2 (en) * 2006-08-28 2008-03-06 The Ohio State University Research Foundation Compositions for reducing cell adhesion to bubbles
US8178527B2 (en) * 2006-10-02 2012-05-15 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
SI2134374T1 (sl) * 2007-03-14 2014-03-31 Bionsil S.R.L. In Liquidazione Inhibitorji btk za rabo pri zdravljenju na kemoterapevtska zdravila rezistentnih epitelijskih tumorjev
EP2240168B1 (en) * 2008-01-08 2014-05-14 The Johns Hopkins University Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
US8710104B2 (en) 2008-11-07 2014-04-29 Triact Therapeutics, Inc. Catecholic butanes and use thereof for cancer therapy
EP2538935B1 (en) 2010-02-22 2014-11-05 The Johns Hopkins University Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine
WO2012145575A2 (en) * 2011-04-21 2012-10-26 Children's Hospital Medical Center Therapy for leukemia
US10342767B2 (en) 2011-04-21 2019-07-09 Children's Hospital Medical Center Therapy for kinase-dependent malignancies
US9084779B2 (en) 2011-05-31 2015-07-21 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
CN105902526A (zh) * 2016-05-06 2016-08-31 兰州大学 马索罗酚在制备治疗包虫病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289506A4 (en) * 1986-11-19 1990-12-12 Chemex Pharmaceuticals, Inc. Lipoxygenase inhibitors
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
WO2006014669A2 (en) * 2004-07-20 2006-02-09 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505567A (ja) * 2012-02-03 2015-02-23 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｎｄｇａ誘導体およびソラフェニブを含む組成物、ならびにがんの処置におけるこれらの使用
JP2016516007A (ja) * 2013-02-26 2016-06-02 トリアクト セラピューティクス，インク． 癌治療
JP2016521278A (ja) * 2013-05-02 2016-07-21 ヘルパービー セラピューティクス リミテッドＨｅｌｐｅｒｂｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ノルジヒドログアヤレト酸およびアミノグリコシドの組み合わせ

Also Published As

Publication number Publication date
EP1848418A2 (en) 2007-10-31
CN101437505A (zh) 2009-05-20
CA2583336A1 (en) 2006-04-20
US20080207532A1 (en) 2008-08-28
WO2006041902A2 (en) 2006-04-20
EP1848418A4 (en) 2010-09-08
AU2005294432A1 (en) 2006-04-20
WO2006041902A3 (en) 2009-04-16
MX2007004025A (es) 2007-06-11

Similar Documents

Publication Publication Date Title
JP2008520548A (ja) 薬剤耐性癌、薬剤耐性ウイルス感染症および薬剤耐性微生物感染症におけるノルジヒドログアヤレト酸誘導体の使用
US20160106721A1 (en) Human therapeutic agents
KR102033305B1 (ko) 아스피린 및 다중 키나아제 억제제를 포함하는 항암제 내성 치료용 조성물
JP5440985B2 (ja) メラノーマの治療
RU2002102709A (ru) Лекарственное средство, обладающее защитным действием в отношении окислительно-токсических и прежде всего кардиотоксических соединений
JP2009536956A (ja) 抗癌治療法
JP2019513812A (ja) 化学療法の改善
JP2010530375A (ja) トリヒドロキシ−クロメン−オン誘導体を含む医薬組成物
WO2004002465A1 (ja) NF-κB阻害剤を含む医薬組成物
TWI614029B (zh) 新穎醫藥組成物及其用途
CN108883123B (zh) 配糖生物碱组合及其各种用途
CN1200712C (zh) 用于治疗癌症的含喜树碱和1,2－二苯乙烯衍生物的组合物
EP3043809B1 (en) Filipendula vulgaris extract and uses thereof
JP2017193591A (ja) 腫瘍細胞選択的抗がん剤
FR3056108A1 (fr) Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif
KR102694803B1 (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
KR101945783B1 (ko) 항암치료 효과 증강용 조성물
HK1131740A (en) Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
JP2007186511A (ja) 癌化学療法
WO2013026454A1 (en) Treatment of clinical conditions with anthracyclines
Qu et al. Induction of apoptosis in human hepatocellular carcinoma cells by synthetic antineoplaston A10
JP2025148753A (ja) がん抑制剤およびがん抑制用医薬
WO2024249855A1 (en) Combination therapy comprising kit inhibitors for use in the treatment of cancer
JPS61129124A (ja) 抗腫瘍剤
JP2005239634A (ja) 乳ガン細胞増殖阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081002

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090714

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110303